Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
248 participants
INTERVENTIONAL
2023-10-12
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trial to Evaluate the Effectiveness of a Digital Therapeutics in Adults Diagnosed With Major Depressive Disorder
NCT04770285
Use of a Digitally Enabled App With Clinical Team Interface in the Management of Depression
NCT04891224
Mobile Technology to Engage and Link Patients and Providers in Antidepressant Treatment (MedLink)
NCT02583230
Effects of Treatment on Decision-making in Major Depression
NCT01916824
A Closed-loop Assessment and Treatment Platform for Unipolar Depression and Anxiety
NCT02948036
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention app
Digitally-delivered self-guided intervention for depression accessed via mobile app
Intervention app
An app-based intervention for depression
Control app
An app based control condition
Control app
An app with non-therapeutic content
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intervention app
An app-based intervention for depression
Control app
An app with non-therapeutic content
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant is at least 13 years of age
* Willing and able to provide informed consent; if under 18 years of age, willing and able to provide assent, and has a legal guardian willing and able to provide consent
* Primary diagnosis of Major Depressive Disorder (MDD)
* Under the care of a United States (U.S.)-based licensed healthcare provider and willing and able to provide contact information for the provider and sign a HIPAA release that allows investigator to contact provider
* Fluent and literate in English
* Has access to a compatible device and operating system (i.e., capable of installing the app from the Google Play or Apple App Store) and regular internet access
* Located in the continental U.S., Hawaii, or Alaska, and not planning to leave the U.S. during the primary study period
Exclusion Criteria
* Has received certain types of psychotherapy within the last 6 months
* Has changed prescribed psychotropic medication (initiation or change in dose) within the past 30 days
* Plans to initiate or change treatment (e.g., psychotherapy, psychotropic medication, and/or other psychosocial treatment) for a mental health disorder during study intervention period
* Suicidal behavior within the past year
* Active suicide ideation with intent within the past 3 months
* Previously participated in user testing or a clinical study at Limbix Health Inc. or Big Health Inc. (such as the STAND study or Rise study), or have used a Limbix app
* Participated in any other clinical research involving an intervention or treatment within the past 60 days
* Plans to participate in any other clinical research involving an intervention or treatment during the study intervention period
* Living in the same household as another participant in the study (e.g., a sibling)
* Has a diagnosis of MDD with psychotic features or comorbid Psychotic Disorder
* Has a concurrent diagnosis of (or has been treated for) bipolar disorder I and II or severe substance use disorder within the past year
* Has treatment resistant depression
* Is employed by Big Health Inc., or is a collaborator, associate, or relation of Big Health Inc. staff
* Any condition, comorbidity, or event (other than the above) that, in the opinion of the investigator, will prevent the participant from adhering to the protocol or benefitting from the intervention, or will prevent investigators from being able to ensure safety
13 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Duke University
OTHER
National Institute of Mental Health (NIMH)
NIH
Big Health Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Big Health, Inc.
San Francisco, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BH-SP-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.